Insider Selling: Pulmonx (NASDAQ:LUNG) CEO Sells 67,813 Shares of Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 67,813 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the sale, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pulmonx Price Performance

LUNG traded down $0.09 on Wednesday, hitting $1.44. The company had a trading volume of 579,968 shares, compared to its average volume of 360,844. Pulmonx Corporation has a 52-week low of $1.31 and a 52-week high of $8.71. The stock has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $1.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86.

Institutional Investors Weigh In On Pulmonx

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Susquehanna Portfolio Strategies LLC acquired a new position in Pulmonx during the fourth quarter valued at $133,000. Engineers Gate Manager LP purchased a new stake in Pulmonx during the 4th quarter worth approximately $106,000. ADAR1 Capital Management LLC raised its stake in Pulmonx by 65.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company’s stock valued at $785,000 after purchasing an additional 140,913 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Pulmonx by 144.6% in the fourth quarter. AQR Capital Management LLC now owns 58,919 shares of the company’s stock valued at $130,000 after buying an additional 34,828 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Pulmonx in the 4th quarter worth approximately $31,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research note on Friday, February 20th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.81.

Pulmonx News Roundup

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year credit facility of up to $60 million with Perceptive Advisors that includes a $40M term loan (with an option for an additional $20M tied to revenue milestones). Management says the financing extends debt maturity to 2031 and strengthens the balance sheet to support commercial and clinical priorities. Article Title
• Positive Sentiment: Q4 results showed improvement vs. a year ago: narrower GAAP loss ($0.25/sh) and adjusted EBITDA loss improved; full‑year 2025 revenue rose to $90.5M (up 8% YoY) and gross margin expanded to ~78% in Q4 — evidence of operating leverage and cost reductions. Article Title
• Neutral Sentiment: Management issued 2026 revenue guidance of $90M–$92M and expects ~75% gross margin with operating expenses $113M–$115M — guidance gives visibility but comes in below some analyst estimates, leaving mixed signals on near‑term topline momentum. Article Title
• Negative Sentiment: Several insiders sold stock on March 2 (including CEO Glendon E. French III, General Counsel David A. Lehman, CCO Geoffrey Beran Rose and Senior staff), representing multiple percent reductions in their holdings — heavy insider selling can pressure sentiment and amplify downside. SEC filings: CEO sale CEO Form 4, Lehman GC Form 4, Beran Rose CCO Form 4, Srikanth Radhakrishnan Form 4
• Negative Sentiment: Q4 U.S. revenue declined (~11% YoY) and total Q4 revenue was down ~5% YoY, signaling softer commercial momentum in Pulmonx’s largest market — the company emphasized a transition plan to reaccelerate U.S. sales, but near‑term growth risk weighed on the stock. Article Title

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.